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Abstract: Histone lysine demethylases (KDMs) are involved
in the dynamic regulation of gene expression and they play
a critical role in several biological processes. Achieving
selectivity over the different KDMs has been a major challenge
for KDM inhibitor development. Here we report potent and
selective KDM5 covalent inhibitors designed to target cysteine
residues only present in the KDM5 sub-family. The covalent
binding to the targeted proteins was confirmed by MS and
time-dependent inhibition. Additional competition assays
show that compounds were non 2-OG competitive. Target
engagement and ChIP-seq analysis showed that the com-
pounds inhibited the KDM5 members in cells at nano- to
micromolar levels and induce a global increase of the
H3K4me3 mark at transcriptional start sites.
Histone proteins can be covalently modified by a plethora
of post-translational marks including methylation. These
modifications modulate chromatin structure which impacts
gene expression, chromosome packaging and DNA damage
repair. Methylation is a reversible process regulated by
histone methyltransferases (HMTs) and lysine demethylases
(KDMs) that control the methylation state (mono-, di-, or tri-
methylation) of lysine residues in histone tails.[1] The larger
class of KDMs, the Jumonji-C domain containing lysine
demethylases (JmjC-KDMs) utilize FeII and 2-oxoglutarate
(2-OG) to oxidise methylated lysine substrates to form an
unstable hemiaminal which fragments to the demethylated
lysine and formaldehyde.[2]
JmjC-KDMs are a family of 20 human enzymes which are
further categorized into subfamilies KDM2-7.[3] There are
four enzymes in the KDM5 subfamily (KDM5A-D) which
can all demethylate di- and tri-methylated lysine 4 of
histone 3 (H3K4me2/3), ubiquitous histone marks necessary
for transcriptional activation. Various studies have linked the
KDM5s to different cancers, in particular overexpression of
KDM5B has been observed in prostate, gastric, breast,
ovarian and hepatic cancer cells.[4] KDM5B also has a role
in development by blocking differentiation of embryonic and
hematopoietic stem cells.[5] The KDM5s have therefore
become increasingly popular targets for chemical probe and
drug discovery to gain a greater understanding of their role in
biology and as oncology targets.
Several small-molecule inhibitors of KDM5s have been
reported.[6] They bind to KDM5s through coordination to the
active site FeII in the 2-OG binding site and form a salt bridge
with a conserved lysine or hydrogen bond to a conserved
tyrosine residue in the KDM5 subfamily. Although nano-
molar enzyme IC50 values are reported, cellular activities are
commonly much weaker which has been attributed to
competition of the inhibitors with higher levels of competing
substrate in cells (2-OG& 1 mm)[7] compared to that used in
biochemical assay conditions (low mm range), a factor known
to reduce kinase inhibitor efficacy.[8] Although KDM5
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inhibitors have shown good selectivity over KDM2/3/6,
selectivity over the KDM4 subfamily has proven more
challenging as the primary binding residues of the catalytic
domain are conserved in KDM4 and KDM5. Selectivity has
only been achieved through structural changes in the
secondary shell. For example, cyanopyrazole CPI-455 is
a potent, selective KDM5 inhibitor with nanomolar enzyme
IC50, but micromolar cellular IC50.
[9] Further optimisation led
to tert-butyl pyrazole 1[10] which showed improved cellular
activity (Figure 1B). Potent KDM5 inhibitors, such as 2,
incorporating a 8-pyrazolopyridopyrimidinone core were
published, however this series suffered from poor selectivity
over KDM4 and poor cellular potency despite cellular
permeability.[11]
Here we report two series of KDM5 selective covalent
inhibitors based on cyanopyrazole CPI-455 and pyridopyr-
imidinone 2 with improved selectivity that target key
cysteines exclusive to the KDM5s. Irreversible binding of
the protein to the inhibitor resulted in reduced competition
with the 2-OG cosubstrate and maintained their cellular
activity despite low cellular permeability. Covalent inhibitors
are potentially more selective and potent, with better cellular
efficiency and can require less frequent and lower doses,
although this can be offset by poor selectivity with the cellular
cysteinome. Covalent inhibitors can also be used as proteomic
tools for both covalent and non-covalent drugs.[12]
Based on alignments of the JmjC-KDMs, two cysteine
residues were identified as potential nucleophiles for covalent
modifications in the KDM5 family. C497 in KDM5B was
identified as a non-catalytic residue close to the binding site
present only in the KDM5 members. In addition, C480 was
identified as a unique residue in KDM5B, so improved
selectivity could be achieved over KDM4s as well as
KDM5A/C/D (Figure 1A). The irreversible binding of the
covalent inhibitors to KDM5s could also reduce competition
with 2-OG to improve their cellular activity.
C480 is positioned close to the binding site of previously
reported inhibitor[11] 2 and was suitable for the design of
cysteine-selective electrophiles based on this scaffold. 8-
Pyridopyrimidinone-based covalent inhibitors 3–6 (PP series)
(Figure 1D) were synthesised (Schemes S1, S2 in the Sup-
porting Information) and acrylamide 3 was co-crystallised
with KDM5B to determine the binding mode. Bidentate
metal coordination and salt bridging/hydrogen bonding to
K517/Y425 was observed with inhibitor 3 and a covalent bond
was seen between the C480 sulfur and acrylamide b-carbon
(Figure 1C).
A second series of KDM5 covalent inhibitors 7–11 (PZ
series) (Figure 1E) were also designed and synthesized
(Schemes S3, S4) to target C497. X-ray crystal structures of
7 and 10 showed the reactive chloroacetyl and acrylamide
moieties within proximity of C497 sulfur (7, 5.8c; 10, 11.7 c)
(Figure S1) although no covalent bond was seen in the crystal
structure. The acrylamide of 10 was positioned further from
C497 however compound flexibility could position it within
covalent bonding distance. Both compounds maintained the
key coordination of the nitrile to the metal centre and H-
bonding interactions of the carbonyl oxygen.
Since covalent inhibitors possess time-dependent inhib-
ition due to the kinetics of covalent binding to the protein,
their activity was better assessed through determination of
the kinetic parameter kinact/Ki, rather than a simple IC50. These
parameters were calculated by using an established method to
derive Ki and kinact directly from time-dependant IC50 values
(Table S1). IC50 values were measured using an AlphaScreen
assay[13] by pre-incubating the compounds with KDM5B at
different time points ranging from 0 to 120 minutes and the
kinact and Ki values determined as previously described.
[14]
In the PP series, chloroacetamide 5 was the most potent
with the highest kinact/Ki (40X 10
3m@1 s@1) and although
acrylamide 4 was less active than 5 with (kinact/Ki 7.4X
103m@1 s@1) it showed a drop in IC50 of 12-fold after an hour
incubation (Figure 2A). Dimethylamino crotonamide 6 was
less potent than the acrylamide 4 with a kinact/Ki of 6.1X
103m@1 s@1. Acrylamide 4 was 5-fold more potent than the
corresponding piperazine acrylamide 3 (kinact/Ki 1.4X
103m@1 s@1).
In the PZ series, chloroacetamide 7 showed the greatest
kinact/Ki (25X 10
3m@1 s@1) with an IC50 drop of 27-fold upon pre-
incubation (Figure 2A). Both acrylamide 10 and chloroacet-
amide 11 had comparable kinact/Ki values of 20X 10
3 and 19X
103m@1 s@1, while the phenyl analogues 8 and 9 showed the
Figure 1. A) KDM alignment at positions C480 and C497 (KDM5B
numbering). B) Reported KDM5 inhibitors CPI-455, 1 and 2. C) Overlay
of compound 2 docked in the X-ray structure of 3 (green) in KDM5B
(PDB ID 6EIN). D) PP compounds. E) PZ compounds. *IC50 (mm).
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lowest kinact/Ki ratio with 6.9X 10
3 and 5.8X 103m@1 s@1, respec-
tively. The larger drop in IC50 with the PZs compared to the
PPs was likely due to the greater contribution of covalency to
their potency. Overall, compounds in both series possessed
time-dependent inhibition through covalent binding to
KDM5B leading to potent nanomolar IC50 values.
As well as improving their potency, the addition of
a covalent electrophile to the inhibitors was expected to
reduce competition with 2-OG. IC50 values of both non-
covalent (1 and 2) and covalent inhibitors (4 and 7) were
therefore determined at different concentrations of 2-OG up
to 1000 mm (Figure 2B,C).
In the PP series, the non-covalent analogue 2 showed an
approximately 500-fold drop in potency from 0.5 mm up to
1000 mm while the covalent inhibitor 4 showed only an 18-fold
lower potency at the high 2-OG concentration. At 1 mm 2-
OG, 4 was 4-fold more potent with an IC50 of 110 nm than 2
which we attribute to improved competition from 2-OG
compared to 2 by a factor of 25.
As reported,[9] even the non-covalent cyanopyrazoles
CPI-455 and 1 are less competed by 2-OG than the PP
series, with compound 1 showing a drop in potency of only 8-
fold in the range of 2-OG concentrations measured. As PZ
compound 1 and PP compound 2 have similar binding modes
based on their crystal structures, it is not clear why they show
such different competition behaviour. But the covalent PZ
inhibitor 7 was significantly more potent than non-covalent
PZ 1 with an IC50 at the top 2-OG concentration of 10 nm and
showed only a small shift in potency of 4-fold with 2-OG
concentration. The addition of covalent inhibition to the PZs
improved the potency as well as the competition with 2-OG.
Covalent inhibitors therefore represent an excellent strategy
for solving the issues with KDM inhibitors in which high 2-
OG competition could explain their poor cellular activities.
A panel of JmjC KDMs was tested by AlphaScreen to
determine the selectivity of the compounds (Table S2). IC50
values were measured at 120 minutes when the inhibition of
the covalent inhibitors against KDM5B had levelled off
(Figure 2A). All the compounds from both series presented
selectivity towards KDM5s, with the highest potency for the
most closely related KDM5A and 5B. For the PZ series, the
most potent compounds against KDM5B contained the 2-
chloroacetamide group, with 7 being the most potent of the
PZ series (KDM5A/B IC50 10 nm) and showed the best
selectivity profile (Table S3). In the PP series the covalent
compounds tested showed high activity with IC50 in the low
nanomolar range against most KDM5 family members.
Both PP and PZ series showed the greatest selectivity
over KDM2A and 3Awith selectivity from 200- to 1500-fold.
The covalent inhibitors also demonstrated good selectivity
over the most closely related KDM4 subfamily members. In
the PP series, methylbenzylamine covalent inhibitors 4–6
showed greater than 20-fold selectivity over the KDM4
family, in particular 5 was more than 60-fold less active on
KDM4B. We attribute this selectivity for KDM5B with the
covalent PP inhibitors to binding to C480. In the PZ series, all
compounds were more than 50-fold selective over all the
KDM4 family members, with compounds 7 and 10 having
> 500-fold selectivity over KDM4A/B.
When comparing the activity of the compounds in the
KDM5 family members, both series were equipotent against
KDM5A/B/D, but 30–100-fold selective over KDM5C. In the
PP series, compound 6 was the most selective with greater
than 7-fold selectivity for KDM5B over KDM5A/C/D which
could be explained by specific binding to C480. In the PZ
series, the most selective compound was chloroacetamide 11
showing the highest selectivity for KDM5B with more than
100-fold over KDM5C.
Covalent binding of the inhibitors with KDM5B was
confirmed through MS-labelling experiments (Figure 3). PP
compound 3 was incubated with KDM5B and the resulting
MS spectra showed a minor set of peaks relating to
unmodified KDM5B (m/z 55153) and a major peak relating
to protein–inhibitor adduct with the correct mass shift (Dm/z
379) (Figure 3A). Compounds 4–6 were incubated with
KDM4B and KDM5C under the same conditions as with
KDM5B (Figure S2) andMS showed only unmodified protein
peaks as expected for these proteins that do not contain
a cysteine at C480 as in KDM5B. The specific covalent
binding to KDM5B explains the improved selectivity over
KDM5C and KDM4B compared to non-covalent inhibitor 2.
Digestion of the protein–inhibitor adduct and further
analysis by LCMS/MS allowed mapping of the inhibitor
reactive residue, confirming that compound 3 was binding
specifically to the desired C480 and not to other cysteines in
KDM5B (Figure 3B, green box) in agreement with X-ray
crystal structure (Figure 1C).
Similarly, incubation of 7with KDM5B resulted in protein
MS peaks from addition of the compound (Dm/z 351)
(Figure 3A). LC-MS/MS analysis (Figure 3B) showed that
Figure 2. A) Time-dependent inhibition of covalent inhibitors 4 and 7. B,C) 2-OG competition assay with non-covalent variants (1 and 2) and
covalent inhibitors (4 and 7).
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although there was good coverage of the native protein
(> 90%) including 3 peptides containing C497, with the
inhibitor modified KDM5B, the peptide containing the target
C497 was the only sequence that was not observed (Figure 3B
light blue box). As this peptide was observed in the
unmodified protein, the addition of the compound appears
to have prevented the detection of the peptide in the covalent
adduct suggesting that C497 was the site of binding. Com-
pounds 4, 7 and 9 were also incubated with PCAF[15] and
NUDT7 (PDB ID 5QHH), two enzymes known to have
covalent inhibitors, but no labelling was observed, demon-
strating the selectivity for KDM5B (Figure S3).
With confirmation of potent and selective binding to
recombinant KDM5 targets, we wanted to show cellular
target engagement. We developed a PZ-based cell-permeable
fluorescent tracer assay to quantify the engagement of
compounds with KDM targets that are fused to NanoLuci-
ferase.[16] An aliphatic amino-terminal linker on a PZ deriv-
ative was attached to the fluorescent dye NanoBRET590
U to
generate a tracer compound that interacts with the NanoLuc-
fused KDMs (Figure S4).
The tracer was tested in transfected NanoLuc-KDM4s,
KDM5s and KDM6B in the presence of compound 1, showing
that the tracer produced significant BRET signal in a dose-
dependent manner with all the KDM5 family members
(KDM5A-D), but no BRET signal for any of the KDM4s or
KDM6B, demonstrating the selectivity of the tracer (Fig-
ure S5). Cellular activity of the most relevant PP and PZ
compounds was then evaluated (Table 1, Figure 4A, Fig-
ure S6). In the PZ series, phenyl-containing compounds 8 and
9, showed the best activity in cells (0.53 and 0.30 mm).
However, compounds 7, 10 and 11 showed micromolar IC50
values, which are more than a 100-fold weaker than their in
vitro activity, probably due to their low logP and poor cell
permeability.
Compound 4 was the only example of the PP series that
showed some activity in cells, with an IC50 of 10.6 mm, in the
same range as the non-covalent compound 2 (IC50 8.8 mm).
For both the PP and PZ compounds, the similar cellular
potency compared to their non-covalent analogues can be
explained due to their high polarity as measured clogP and
poor cell permeability as measured by Caco-2 (Table 1). Non-
covalent compoundsCPI-455, 2 and 3 have good permeability
(Caco-2 AB 7.5–17.2X 10@6 cms@1) but despite being much
less cell permeable (Caco-2 AB< 1.5X 10@6 cms@1), the
covalent compounds are as potent in cells as their non-
covalent analogues, presumably due to their better 2-OG
competition.
Figure 3. A) Intact mass spectra of covalent binding by MS. B) Peptide mapping of KDM5B after treatment with compounds 3 and 7. Observed
peptides for native protein (light red box), compound 3 adduct (green box) and compound 7 adduct (light blue box).
Table 1: Biochemical and cellular properties of the PZ and PP series.
Cmpd clogP
[a]
Papp
[b]
IC50
(2-OG
1 mm)
[d]
IC50
(2-OG
1 mm)
[d]
2-OG
shift[e]
KDM5B
nano-
BRET
IC50 [mm]
ChIP-seq
conc
[mm]
2 1.1 11.8 0.003 0.506 169 8.8 ND
3 @1.8 <1.5 0.184 ND ND >30 ND
4 @1.5 <1.5 0.009 ND ND 10.6 ND
5 @0.94 <1.5 0.01 0.11 11 >30 2.0
6 @0.58 <1.5 0.004 0.094 26 >30 ND
CPI-455 1.3 17.2[c] 0.003[c] ND 2.0[c] 0.40 ND
1 0.65 7.5[c] 0.015 0.377 3.9 0.34 ND
7 @0.74 <0.76 0.007 0.010 2.0 2.5 2.0
8 0.68 <0.76 0.049 0.041 1.8 0.53 2.0
9 0.92 <0.76 0.065 0.059 1.9 0.30 ND
10 @0.89 <0.76 0.017 0.017 2.4 5.5 ND
11 @1.3 <1.4 0.009 0.008 1.3 8.6 ND
[a] Calculated with ChemDraw version 16.0.1.4. [b] Determined in Caco-2
cells. Values are A to B (10@6 cms@1). [c] Previously reported values in
MDCK cells.[9, 10] [d] AlphaScreen in vitro activity in KDM5B. [e] Calculated
as ratio of IC50 values determined at 2-OG concentrations of 1 mm and
1 mm.
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Immunofluorescence-based assays have been previously
used to analyse global changes in H3K4me3 as a measure of
KDM5 activity, but the global change can be affected by other
factors such as cytotoxicity.[17] We therefore employed chro-
matin immunoprecipitation and sequencing (ChIP-seq) as
a more accurate method to quantify the H3K4me3 level at
transcriptional start sites (TSS) as a read-out for inhibition of
KDM5 activity. Cytotoxicity of the compounds was first
assessed to show that with the exception of 5, compounds
were not cytotoxic in HEK cells (Figure S7). Compounds 4, 7
and 9 were selected for H3K4me3 ChIP-seq experiments and
quantification.[18]
After sequencing and normalisation, read coverage was
evaluated and coverage plots were plotted across all genes
revealing significant increases of H3K4me3 levels around TSS
(Figure 4B). ARID3B, known to be highly expressed in HEK
cells,[19] was chosen as a representative gene and all three
compounds doubled H3K4me3 levels (Figure S8).
In conclusion, covalent inhibitors in the PP and PZ series
that target distinctive cysteine residues in the KDM5 family
has been shown to target lysine demethylases to overcome
high cellular 2-OG levels and improve KDM selectivity.
Target engagement in cells was demonstrated using a novel
NanoBRET assay and functional effects of the covalent
inhibitors was shown by increase in H3K4me3 at TSS in
HEK293 cells.
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Figure 4. A) Cellular activity of compound 9 by NanoBRET assay.
B) Distribution of H3K4me3 around transcriptional start sites (TSS).
Densities of ChIP-seq reads for H3K4me3 and input in HEK293 cells
treated with DMSO and compounds 4, 7, 9 and non-covalent reference
compound KDOAM-25.
Angewandte
ChemieCommunications
519Angew. Chem. Int. Ed. 2019, 58, 515 –519 T 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
